Physician profile
Ali Ameri
NPI 1164681540
$9,522.10
in general payments reported to CMS, 2019-2025
36 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,755 · 2020: $692 · 2021: $1,270 · 2022: $1,738 · 2023: $1,497 · 2024: $311 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Long Term Medical Supply Or Device Loan: $299 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.35 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $268.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $2,943.00 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $1,083.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $884.09 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $672.24 | 2021-2025 | Opdivo |
| Gilead Sciences, INC. | $552.32 | 2021-2023 | Trodelvy |
| Seagen INC. | $495.89 | 2019-2023 | |
| Glaxosmithkline, LLC. | $259.35 | 2021-2023 | Shingrix |
| Incyte Corporation | $251.30 | 2019-2023 | |
| Sobi, INC | $245.53 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $239.14 | 2019-2021 | |
| Genzyme Corporation | $238.86 | 2021-2025 | |
| Pfizer INC. | $209.00 | 2019-2021 | |
| Daiichi Sankyo INC. | $162.91 | 2022-2023 | Injectafer |
| Astellas Pharma US INC | $149.72 | 2021-2023 | Padcev |
| Alexion Pharmaceuticals, INC. | $139.50 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $121.80 | 2019 | |
| Adaptive Biotechnologies Corporation | $110.88 | 2023 | Clonoseq |
| Abbvie INC. | $109.92 | 2019 | |
| Mirati Therapeutics, INC. | $103.93 | 2023 | Krazati |
| Genentech USA, INC. | $72.39 | 2020-2023 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $67.77 | 2019-2022 | |
| Janssen Biotech, INC. | $63.16 | 2021-2022 | |
| Puma Biotechnology, INC. | $45.93 | 2022-2023 | |
| Celgene Corporation | $34.66 | 2022 | |
| Secura Bio, INC. | $34.53 | 2021-2022 | |
| Taiho Oncology, INC. | $34.29 | 2023 | |
| Kite Pharma, INC. | $31.39 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $24.56 | 2019 | |
| Global Blood Therapeutics, INC. | $22.12 | 2022 | |
| Morphosys, US INC. | $21.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.13 | 2022 | |
| Exelixis INC. | $18.63 | 2022 | |
| Emd Serono, INC. | $15.58 | 2022 | |
| Amgen INC. | $15.45 | 2023 | Lumakras |
| Lilly USA, LLC | $13.29 | 2023 | Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $13.12 | 2023 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Ameri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.